Anondita Medi. announces a new order win

TCV: N/A — insufficient evidence to estimate. The 80 million-unit order does not include a disclosed per-condom contract price, delivery schedule, or clarity on whether taxes, packaging and freight are included. The calculation would be:

`TCV = 80 million condoms × contracted price per condom`

The latest Annual Report figures needed for the capacity comparison are also not available in the cited material. Therefore, a quantified comparison cannot be made against:

• Total installed capacity: `80 million ÷ total installed annual capacity`
• Recent annual production: `80 million ÷ annual production volume`

The key interpretation depends on the delivery period: an 80 million-unit order delivered in one year would be compared with one year’s capacity and production, while a multi-year supply contract would represent only the relevant annual shipment volume. No defensible TCV or capacity-utilisation percentage should be stated without the contract price and Annual Report production figures.

The timeline and supply feasibility cannot be established from the disclosed evidence. L1 status is not the same as a secured order: the formal LoA, contractual delivery period, monthly dispatch schedule, and any production-readiness statement are not reported. Therefore, no defensible date can be assigned for the LoA or first supply.

LoA and supply schedule

• LoA: No expected issuance date is reported. The L1 designation should be treated as a pre-award stage until the procuring authority issues the LoA and the company confirms the contract.
• Supply commencement: No start date, lot size, monthly run-rate, or completion deadline is reported for the 80-million-unit requirement.
• Key dependency: The actionable timeline begins with LoA issuance, followed by purchase-order terms, technical approvals, product specifications, and the buyer’s delivery milestones. These terms could materially determine whether supply is immediate, phased, or contingent on further approvals.

Capacity and inventory assessment

There is no evidence to conclude that the company can fulfil 80 million units from existing inventory or spare capacity without additional capex:

• Current inventory, specifically, is not reported; current assets of Rs 537.44 Crores cannot be treated as inventory ^[1].
• Installed capacity, utilization, spare capacity, production rate, and existing order commitments are not reported.
• Capital work in progress is Rs 1.92 Crores ^[2], but this does not establish either available capacity or the absence of further capex requirements.
• The latest reported current liabilities of Rs 1,447.50 Crores exceed current assets of Rs 537.44 Crores, a derived current-assets-to-current-liabilities ratio of approximately 0.37x ^{[1] [3]}. This does not determine production capacity, but it suggests that working-capital funding could become relevant if the contract requires substantial raw-material procurement or inventory build-up.

Analyst inference: The no-capex case is unproven rather than disproven. It would require company confirmation of at least 80 million units of available finished-goods inventory or sufficient unutilized production capacity, together with the delivery rate and working-capital terms under the LoA. News and analyst coverage were not retrieved, so there is no independently reported LoA timing or contract-schedule evidence to narrow the timeline.

Conclusion: A source-backed comparison is not possible here. CMSS tender-level margins and Anondita’s recent blended EBITDA margins are not reported in the cited evidence, so it would be incorrect to conclude that CMSS work is either below or above the company’s blended margin.

• The latest structured metrics available for Anondita are current ratio of 0.37x in Q2 FY26 and 0.37x in Q3 FY26; EBITDA margin and tender economics are not included ^{[4] [5]}.
• CMSS contract-level revenue, cost, contribution margin, and EBITDA margin are not separately disclosed in the cited material.
• A valid comparison would require the same period and basis—preferably consolidated EBITDA margin versus tender EBITDA after fulfilment, logistics, compliance, working-capital, and other contract-specific costs. Comparing tender gross margin with company EBITDA margin would be misleading.
• Anondita’s track record of executing similar high-volume, low-margin government contracts is also not demonstrated by the cited evidence. No contract history, awarded volumes, realised margins, or completion record for comparable CMSS tenders is available to substantiate that claim.

Analyst read: Treat the tender opportunity as an unverified margin and execution case rather than assuming that government volume will translate into reported EBITDA. The key diligence items are prior CMSS order wins and fulfilment history, repeat-customer evidence, tender-level contribution margins, receivable cycles, and whether management has quantified the impact on consolidated EBITDA.